The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
AgeUp to 22
SponsorPedAL BCU, LLC

About this trial

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Eligibility criteria

Qualifiers

Patients must be less than 22 years of age at the time of study enrollment

Patient has known or suspected relapsed/refractory (including primary refractory) AML as defined in protocol

This includes isolated myeloid sarcoma

Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS)

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Biospecimen Collection

Treatment groups

960 Participants
are divided into 1 treatment group

Locations

183
Australia
The Children's Hospital at Westmead2145, WestmeadNew South Wales, Australia
Queensland Children's Hospital4101, South BrisbaneQueensland, Australia
Royal Children's Hospital3052, ParkvilleVictoria, Australia
Perth Children's Hospital6009, PerthWestern Australia, Australia

Sponsors and collaborators

PedAL BCU, LLC

Lead sponsor

Children's Oncology Group

Collaborator

National Cancer Institute (NCI)

Collaborator